Enorama Pharma Agrees to Convert DS Global Debt and Interest Into Shares at Maturity

• Enorama Pharma will repay outstanding loans from major shareholder DS Global, including interest, through directed share issues at each loan’s maturity.
• New shares will be issued at SEK 0.4 each, with USD debt converted at SEK 10 per USD 1.
• The debt conversion could raise DS Global’s holding above 30% of shares.
• The agreement forms part of efforts to restore equity following the board’s February 13, 2026, decision to prepare a control balance sheet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202611131000BITN____UKPR__SV_20261113-BIT-8974-0) on November 13, 2026, and is solely responsible for the information contained therein.